Generation Photosensitizer Research Articles

Does the in-vitro efficiency of meso-tetrahydroxy-phenyl-chlorin depend on pre-treatment of sensitizer?

The efficiency of a new photosensitizer of the second generation, meso-tetra-hydroxyphenyl-chlorin (mTHPC), which has a strong absorption at 652 nm, was investigated by oxygen consumption measurements and membrane integrity testing. The experiments proved a great increase in the efficiency of mTHPC after preincubation at 37°C for 24 hours. From these findings it can be assumed that tumor cells can be treated in an optimal way with PDT after a longer delay following drug administration.

Experimental and clinical standards, and evolution of lasers in neurosurgery.

From initial experiments of ruby, argon and CO2 lasers on the nervous system so far, dramatic progress was made in delivery systems technology as well as in knowledge of laser-tissue interaction effects and hazards through various animal experiments and clinical experience. Most surgical effects of laser light on neural tissue and the central nervous system (CNS) are thermal lesions. Haemostasis, cutting and vaporization depend on laser emission parameters--wavelength, fluence and mode--and on the exposed tissues optical and thermal properties--water and haemoglobin content, thermal conductivity and specific heat. CO2 and Nd-YAG lasers have today a large place in the neurosurgical armamentarium, while new laser sources such as high power diode lasers will have one in the near future. Current applications of these lasers derive from their respective characteristics, and include CNS tumour and vascular malformation surgery, and stereotactic neurosurgery. Intracranial, spinal cord and intra-orbital meningiomas are the best lesions for laser use for haemostasis, dissection and tissue vaporization. Resection of acoustic neuromas, pituitary tumours, spinal cord neuromas, intracerebral gliomas and metastases may also benefit from lasers as accurate, haemostatic, non-contact instruments which reduce surgical trauma to the brain and eloquent structures such as brain stem and cranial nerves. Coagulative lasers (1.06 microns and 1.32 microns Nd-YAG, argon, or diode laser) will find an application for arteriovenous malformations and cavernomas. Any fiberoptic-guided laser will find a use during stereotactic neurosurgical procedures, including image-guided resection of tumours and vascular malformations and endoscopic tumour resection and cysts or entry into a ventricle. Besides these routine applications of lasers, laser interstitial thermotherapy (LITT) and photodynamic therapy (PDT) of brain tumours are still in the experimental stage. The choice of a laser in a neurosurgical operating room implies an evaluation of the laser use (applications, frequency), of the available budget and costs--including purchase, maintenance and staff training--, and material that will be necessary: unit, peripherals, safety devices and measures, training programme. Future applications of lasers in neurosurgery will come from technological advances and refined experimental applications. The availability of new wavelength, tunable, small sized and "smart" laser units, will enlarge the thermal and non-thermal interactions between laser energy and neural tissue leading to new surgical applications. Tissue photo-ablation, photohynamic therapy using second generation of photosensitizers, updated thermotherapy protocols, are current trends for further use of lasers in neurosurgery.

Purpurins and benzochlorins as sensitizers for photodynamic therapy

Purpurins and benzochlorins are hydrophobic second generation photosensitizers, which have sizable absorption in the 650–780 nm range and exhibit photodynamic activity against tumors after visible light treatment. This review summarizes the published data regarding these compounds: from the spectroscopic, photophysical and photochemical characteristics to the in vivo and in vitro photodynamic inactivation of tumors and normal tissue effects. Some mechanistic studies using both the Sn-etiopurpurin and/or the Cu-benzochlorin derivatives are also reviewed.

Photodynamic therapy: a promising new modality for the treatment of cancer

The first reports on photodynamic therapy (PDT) date back to the 1970s. Since then, several thousands of patients, both with early stage and advanced stage solid tumours, have been treated with PDT and many claims have been made regarding its efficacy. Nevertheless, the therapy has not yet found general acceptance by oncologists. Therefore it seems legitimate to ask whether PDT can still be described as “a promising new therapy in the treatment of cancer”. Clinically, PDT has been mainly used for bladder cancer, lung cancer and in malignant diseases of the skin and upper aerodigestive tract. The sensitizer used in the photodynamic treatment of most patients is Photofrin®, (Photofrin®, the commercial name of dihematoporphyrin ether/ester, containing >80% of the active porphyrin dimers/oligomers (A.M.R. Fisher, A.L. Murphee and C.J. Gomer, Clinical and preclinical photodynamictherapy, Review Series Article, Lasers Surg. Med., 17 (1995) 2–31). It is a complex mixture of porphyrins derived from hematoporphyrin. Although this sensitizer is effective, it is not the most suitable photosensitizer for PDT. Prolonged skin photosensitivity and the relatively low absorbance at 630 nm, a wavelength where tissue penetration of light is not optimal, have been frequently cited as negative aspects hindering general acceptance. A multitude of new sensitizers is currently under evaluation. Most of these “second generation photosensitizers” are chemically pure, absorb light at around 650 nm or greater and induce no or less general skin photosensitivity. Another novel approach is the photosensitization of neoplasms by the induction of endogenous photosensitizers through the application of 5-aminolevulinic acid (ALA). This article addresses the use of PDT in the disciplines mentioned above and attempts to indicate developments of PDT which could be necessary for this therapy to gain a wider acceptance in the various fields.

In situ COMPARISON OF 665 nm and 633 nm WAVELENGTH LIGHT PENETRATION IN THE HUMAN PROSTATE GLAND

The depth of treatment in photodynamic therapy (PDT) of tumors varies with the wavelength of light activating the photosensitizer. New generation photosensitizers that are excited at longer wavelengths have the potential for increasing treatment depths. Tin ethyl etiopurpurin (SnET2), a promising second-generation photosensitizer is maximally activated at 665 nm, which may be significantly more penetrating than 633 nm light currently used with porphyrins in PDT. The penetration of 665 nm and 633 nm wavelength red light in the prostate gland was compared in 11 patients undergoing prostatic biopsies for suspected prostatic cancer. Interstitial optical fibers determined the light attenuation within the prostate gland. Of the 11 patients, 7 had dual wavelength and 4 had single wavelength studies. The mean attenuation coefficients, mueff, for 665 nm and 633 nm wavelength light were 0.32 +/- 0.05 mm-1 and 0.39 +/- 0.05 mm-1, respectively, showing a statistically significant difference (P = 0.0003). This represented a 22% increase in the mean penetration depth and at 10 mm from the delivery fiber there was 1.8 times as much 665 nm light fluence than 633 nm. The mean mueff at 665 nm for benign and malignant prostate tissue were similar (P = 0.42), however, there was significant interpatient variation (mueff ranging from 0.24 to 0.42 mm-1) reflecting biological differences of therapeutic importance. The enhanced light fluence and penetration depth with 665 nm light should allow significantly larger volumes of prostatic tissue to be treated with SnET2-mediated PDT.

Clinical and preclinical photodynamic therapy

Photodynamic therapy (PDT) is a treatment modality that utilizes a photosensitizing drug activated by laser generated light, and is proving effective for oncologic and nononcologic applications. This report provides an overview of photosensitizers, photochemistry, photobiology, and the lasers involved in photodynamic therapy. Clinical and preclinical PDT studies involving Photofrin and various second generation photosensitizers are reviewed.

Assessment of effect of photosensitizers on cytotoxicity of photodynamic therapy in human breast cancer cell cultures

Photodynamic therapy (PDT) might be of clinical value for patients with breast cancer with local recurrences or metastasis. However, there is a need for improved photosensitizers that are effective in combination with laser light and have few, if any, side-effects. We evaluated in vitro the effectiveness of a second generation photosensitizer by testing the influence of laser light on cell cultures of a human breast carcinoma cell line, incubated with meta-tetrahydroxyphenylchlorin (m-THPC) (= Temoporfin). Five thousand MCF-7 cells were plated in 96-well plates. Forty-eight hours before laser treatment, the cells were plated to achieve a monolayer configuration. Twenty-four hours after plating, they were incubated with m-THPC. On day 6 after treatment with m-THPC we lysed the cells to extract the intracellular ATP that correlates with the number of living cells. The ATP-CVA was used to assess the cytotoxicity of the tested photosensitizer m-THPC at various concentrations and the relevant laser light alone prior to their combination after six days of culture. We found a dose-response for m-THPC alone ranging from 2 to 16 micrograms/ml. The calculated inhibition concentration to produce 50% cell kill (IC50) was 4.55 micrograms/ml. We also observed a very low cytotoxicity for laser irradiation alone but a very strong cell kill for the combination of m-THPC together with laser light. PDT gave almost total cell kill at m-THPC concentrations that are not toxic in vitro.

THE PHOTOCHEMICAL PROPERTIES OF FLUOROALUMINUM PHTHALOCYANINE

Fluoride is known to inhibit the photodynamic activity of aluminium phthalocyanine in a variety of biological systems. In order to gain insight into this phenomenon, the effect of fluoride on the photophysical properties of free and albumin-bound chloroaluminum phthalocyanine sulfonate (AlPcSn) were studied. The association constant of NaF with AlPcSn in aqueous solution was measured as 500 +/- 20 M-1. This binding affects the photophysical properties of the dye: the absorption bands in the visible range are blue-shifted by 6-8 nm, and this effect is mirrored in the fluorescence emission spectrum. Human serum albumin significantly quenched the dye fluorescence independent of the presence of fluoride ion. The transient absorption spectrum of the excited dye triplet is unchanged by NaF, but the quantum yield for its generation is increased by 50%, with no decrease in its lifetime. Formation of fluoroaluminum phthalocyanine complexes was also observed in tetrabutylammonium fluoride-assisted solutions in wet acetonitrile. The fluoro-AlPcSn complex is a better photosensitizer for generation of singlet oxygen than the original dye-hydroxyl ion complex, as confirmed using the imidazole-N,N-dimethyl-4-nitrosoaniline method. On the other hand, the fluoro-AlPcSn complex exhibits an intense inhibitory effect on photohemolysis of red blood cells (RBC) even after the cells are washed to remove free dye and fluoride prior to irradiation, indicating that once the dye is attached to the cellular site, the fluoride ligand is no longer prone to displacement (by hydroxyl ion, for example). Nonetheless, it is clear from the spectroscopic data that the new fluoro complex is an efficient sensitizer for photooxidation.(ABSTRACT TRUNCATED AT 250 WORDS)

Photophysics and photochemistry of tetraanthraporphyrazines; attempts to obtain a new generation of photosensitizers

Abstract Linearly benzo-annulated copper porphyrazines, such as octaphenyltetraanthraporphyrazinato-copper and octapentoxytetranaphthoporphyrazinato-copper, with absorption maxima at about 880 nm, were synthesized. These compounds exhibit very low-lying triplets with an energy below the activation energy of singlet oxygen. Therefore they do not generate singlet oxygen. The transient absorption spectra of the T 1 —T x transition were measured. The solvent dependence of the photophysical parameters in the triplet manifold is discussed. On irradiation in the presence of CBr 4 , π-cation radicals are formed.

Spectroscopic studies of tin ethyl etiopurpurin in homogeneous and heterogeneous systems

Tin ethyl etiopurpurin is a promising second generation photosensitizer for photodynamic treatment of cancer. This compound is only poorly soluble in aqueous media and, therefore, needs a delivery system for administration to animals. Successful tumor eradication has previously been reported, following light exposure of rats previously administered with the purpurin formulated as a Cremophor El emulsion, in dipalmitoyl—phosphatidyl—choline liposomes or with gamma cyclodextrins. In this paper, we describe some absorbance and fluorescence studies of tin ethyl etiopurpurin in homogeneous and heterogeneous systems. In general, absorption and emission maxima were found to be red shifted as the environment changed from polar to non-polar. The viscosity and dielectric constant of the medium affected the purpurin fluorescence intensity. The liposome preparations were characterized by particle size determination, differential scanning calorimetry and by sensitizer fluorescence quenching studies. Photobleaching studies also showed variation owing to changes in the environment in which the dye was located.

Phosphazene-bound Rose Bengal: A novel photosensitizer for singlet oxygen generation

In this paper we report the synthesis and the characterization of cyclo- and polyphosphazenes supporting Rose Bengal. These substrates are suitable for the photosensitized generation of singlet oxygen, both in homogeneous and in heterogeneous phase. The efficiency of1O2 production has been measured in homogeneous solution using, as photosensitizer, the cyclophosphazene-bound Rose Bengal and considering, as testing reaction, the oxidation of 1,3-diphenylisobenzofuran; it was found comparable to that of free Rose Bengal in the same experimental conditions.

Activity of phthalocyanine photosensitizers against human glioblastoma in vitro.

In vitro studies utilizing an established human glioblastoma cell line (U87MG) were undertaken to compare the light absorption spectra and photocytotoxicity characteristics of hematoporphyrin derivative (HpD), metal-free phthalocyanine tetrasulfonate (PcS), and aluminum phthalocyanine tetrasulfonate (AlPcS). The peak absorption wavelengths for the compounds studied were: HpD = 630 nm, PcS = 630 nm, AlPcS = 677 nm. Seven different concentrations of each compound (0 to 20 micrograms/ml) were subjected to five different energy levels (40 to 640 joules/cm2) of broad band light (wavelength = 650 +/- 40 nm). Control experiments employing each drug alone and photoactivation alone were also performed. HpD showed a consistent dose-dependent photoactivated cytotoxicity with an abrupt decrease in cell survival when energies of 160 joules/cm2 or more were administered and a drug concentration dependency that resulted in a progressive decline in cell survival beginning at 1.0 microgram/ml. The metal-free PcS had a 10 times greater absorption of light at 675 nm, but only a very weak cytotoxic effect, which occurred at concentrations in excess of 10.0 micrograms/ml and energy levels greater than 320 joules/cm2. AlPcS, however, displayed a 100-fold increase in light absorption at 675 nm when compared to HpD. This was coupled with a decrease in cell survival similar to the HpD curves, but with a much steeper slope of percentage cell kill at lower drug concentrations and energy dosages. The control studies did not result in any appreciable cytotoxic effect. The data suggest that AlPcS holds promise as a second generation photosensitizer in the photodynamic treatment of human gliomas.